Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Researchers at the University of Basel have developed CAR T-cells that target glioblastoma, a notoriously aggressive brain ...

Tiny lab-grown models of human immune systems are helping researchers understand why cancer patients struggle to fight ...

"To address this, we designed a new model that faithfully replicates the unique complexity of human immune biology across ...

Second, not all the cancer cells necessarily have the structure the T-cells can recognize and attack. And third, solid tumors in human tissue have a microenvironment that fends off immune system ...

To better understand why some cancer patients struggle to fight off infections, Georgia Tech researchers have created tiny ...

Solid tumors present specific challenges that make them less treatable with engineered T-cell therapies. These tumors can ...